A software defect in which existing users who had previously configured and enabled the long-acting dose reminder feature in version 1.2.0 or earlier experienced failure of the long-acting dose reminder after updating their app to version 1.2.1. The long-acting dose reminder is an optional feature that, when enabled, triggers a notification at the scheduled time to remind users to take their long-acting insulin dose. The issue was caused by a type cast exception during database migration that occurs upon app update to version 1.2.1 causing a silent failure that prevented the creation of new alerts. Failure to receive the long-acting dose reminder may result in missed or delayed insulin doses, potentially leading to hyperglycemia. Conversely, if users are uncertain whether they took their dose due to the missing reminder, inadvertent duplicate dosing may occur, potentially resulting in hypoglycemia.
✎ GovInfoNow plain-language explainer
Medtronic MiniMed is recalling the MiniMed Go App for iOS and Android because a software defect prevents the long-acting dose reminder from working after updating to version 1.2.1. Users who had previously enabled this feature will no longer receive notifications at their scheduled times. This failure can lead to missed insulin doses or, if users are unsure whether they took their medication, accidental duplicate dosing. Read more at govinfonow.com/recall/1932768-medtronic-minimed-inc-recalls-generic-name-minimed-go-app-generic.
“Medtronic MiniMed Go App Recall: Missed Insulin Doses.” GovInfoNow, updated November 11, 2026. https://govinfonow.com/recall/1932768-medtronic-minimed-inc-recalls-generic-name-minimed-go-app-generic. Based on FDA recall #Z-0265-2027 (https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-0265-2027%22&limit=1).
The FDA announced on Sept. 2, 2026, that Medtronic MiniMed is recalling the MiniMed Go App (versions MMT-8600 for iOS and MMT-8601 for Android) due to a software defect. The hazard involves potential missed or delayed insulin doses, which could lead to hyperglycemia. Owners should update their app to resolve the issue.
A software defect in version 1.2.1 causes the long-acting dose reminder to fail for users who had previously enabled it in version 1.2.0 or earlier. This silent failure prevents new alerts from being created, potentially leading to missed or delayed insulin doses and hyperglycemia. Inadvertent duplicate dosing may also occur if users are uncertain whether they took their dose.
Context
GovInfoNow's records show Medtronic MiniMed has issued 16 other recalls since Nov. 15, 2023. Recent brand recalls include the CareLink Clinic (Sept. 11, 2026), MiniMed Flex Insulin Pump (Aug. 20, 2026), and Medtronic MiniMed 640G Insulin Pump (July 13, 2026). Other recent recalls of similar products include the Tandem t:slim App Recall (July 16, 2026), FreeStyle Libre 14 Day Sensor Recall (Nov. 24, 2025), and Dexcom G7 CGM App recall (April 14, 2026).
How to tell if you have this one
Check if you are using the MiniMed Go App on an iOS device (model MMT-8600) or Android device (model MMT-8601). Verify that your software version is 1.2.1 and that you had previously configured and enabled the long-acting dose reminder feature.
Brand
Medtronic MiniMed
Category
Medical device
Based on the official FDA remedy
What to do — step by step
Check App Version
Verify if your MiniMed Go App is running software version 1.2.1 on iOS or Android.
Monitor Insulin Doses
Be aware that the long-acting dose reminder may not trigger, so you must manually track your scheduled insulin times to avoid missed or duplicate doses.
Where it went and when
Where it was distributed
Distributed nationwide and abroad; the notice names 11 states.
Named in the notice
Covered by “nationwide”
Not listed
FDA distribution: “Worldwide - U.S. Nationwide distribution in the states of AL, CA, CT, FL, LA, MA, MD, NY, OH, PA, and TX. The countries of Austria, Belgium, Denmark, Finland, Germany, Iceland, Italy, Norway, Spain, Sweden, Switzerland, United Kingdom.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Named in the notice: Alabama, California, Connecticut, Florida, Louisiana, Maryland, Massachusetts, New York, Ohio, Pennsylvania, Texas.
Recall timeline
FDA published this recall 56 days after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4Added to GovInfoNow
Dates from the agency record only; steps without a date are left out.
The app is available on the Apple App Store and Google Play Store, with distribution in the U.S. (AL, CA, CT, FL, LA, MA, MD, NY, OH, PA, TX) and several European countries.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #Z-0265-2027 (September 2, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for Z-0265-2027 to see it in context.
Plain-language summary written by qwen3.6:35b-a3b on November 11, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.